Affiliation: Eli Lilly and Company
Kharitonenkov A, Wroblewski V, Koester A, Chen Y, Clutinger C, Tigno X, et al
. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148:774-81 pubmed
..These data support the development of FGF-21 for the treatment of diabetes and other metabolic diseases. ..
Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol. 2009;9:805-10 pubmed publisher
Kharitonenkov A, Shiyanova T, Koester A, Ford A, Micanovic R, Galbreath E, et al
. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-35 pubmed
..Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes. ..
Kharitonenkov A, Dunbar J, Bina H, Bright S, Moyers J, Zhang C, et al
. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol. 2008;215:1-7 pubmed
..All together, these results indicate that betaKlotho and FGFRs form the cognate FGF-21 receptor complex, mediating FGF-21 cellular specificity and physiological effects. ..
Kharitonenkov A, Beals J, Micanovic R, Strifler B, Rathnachalam R, Wroblewski V, et al
. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE. 2013;8:e58575 pubmed publisher